Literature DB >> 10454774

Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis.

A W de Boer1, M Levi, R E Reddingius, J L Willems, S van den Bosch, C H Schröder, L A Monnens.   

Abstract

An increased rate of obstruction of peritoneal dialysis catheters is observed during peritonitis. Hypercoagulation and hypofibrinolysis may explain this increased occurrence. We studied plasminogen activator inhibitor type 1 antigen (PAI-1), tissue-type plasminogen activator antigen (t-PA), D-dimer (DD), plasmin-alpha2-antiplasmin complexes (PAP), and thrombin-antithrombin III complexes (TAT) in 7 children with peritonitis (group A) and 12 children during stable peritoneal dialysis (group B). Albumin, beta2-microglobulin, IgG, and alpha2-macroglobulin were measured for baseline transperitoneal protein transport. After a dwell of 6 h with 1.36% Dianeal, dialysate and serum samples were collected. Dialysate to plasma ratios of all proteins were calculated. During peritonitis (group A) TAT was higher: 34.7 versus 22.0 (P=0.01). PAI-1 was increased in group A: 76.5 versus 22.9 (P=0.004). PAP was decreased during peritonitis (group A): 24.9 versus 39.3 (P=0.01). In group A, DD were decreased. 10.8 versus 26.7 (P=0.002). t-PA was similar in both groups (23.7 in group A vs. 27.7 in group B; P=0.26). In both groups TAT, PAI-1, t-PA, PAP, and DD were significantly higher than in baseline transperitoneal transport, suggesting intraperitoneal production. Hypercoagulability and hypofibrinolysis were present during peritonitis compared with the control situation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454774     DOI: 10.1007/s004670050609

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?

Authors:  Deirisa Lopes Barreto; Annemieke M Coester; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

Review 2.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

Review 3.  Management of peritonitis in children receiving chronic peritoneal dialysis.

Authors:  Franz Schaefer
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Comparison of intraperitoneal antithrombin III and heparin in experimental peritonitis.

Authors:  Sema Akman; Mustafa Koyun; Tekinalp Gelen; Mesut Coskun
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

Review 5.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

6.  Preclinical assessment of adjunctive tPA and DNase for peritoneal dialysis associated peritonitis.

Authors:  Amanda L McGuire; Sophia C Bennett; Sally M Lansley; Natalia D Popowicz; Julius F Varano della Vergiliana; Daniel Wong; Y C Gary Lee; Aron Chakera
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 7.  Dialysis-associated peritonitis in children.

Authors:  Vimal Chadha; Franz S Schaefer; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2009-02-04       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.